Figure 3.

RvE1 treatment enhances MHC II⁻ macrophage recruitment in peritoneal cavity. Mice underwent CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 μg/mouse i.v.) or vehicle (100 μl PBS, 0.1% Ethanol). (A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP. (B) Scattergrams illustrating monocyte/macrophage (identified as Ly6G⁻CD64⁺) and neutrophil (identified as Ly6G⁺CD64⁻) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (C,D) Cumulative data for peritoneal CD64⁺ monocytes/macrophages and Ly6G⁺ neutrophils. (E) Scattergrams illustrating macrophage (identified as CD64^highLy6C^low) and monocyte (identified as CD64^lowLy6C^high) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (F,G) Cumulative data for peritoneal CD64^highLy6C^low macrophages and CD64^lowLy6C^high monocytes. (H) Scattergrams illustrating MHC II⁻ macrophage and MHC II⁺ macrophage positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (I,J) Cumulative data for peritoneal MHC II⁻ macrophages and MHC II⁺ macrophages. Data are expressed as mean ± SEM of four mice for vehicle group and five mice for RvE1 treatment group. Data were analyzed by unpaired Student's t-test. *P < 0.05 vs. CLP + Vehicle group.